The nonprofit scientific research organization IAVI and Merck & Co., Inc. announced today they have entered into an agreement that could enable IAVI to accelerate the entry of a Sudan ebolavirus (SUDV) vaccine candidate that could be deployed in the Republic of Uganda this year.
The Ministry of Health of Uganda has declared a SUDV outbreak in several districts that have claimed about 28 lives since late September 2022.
55,000 Sudan Ebolavirus Vaccine Candidates Coming by Year End
Highest COVID-19 Death Rate for 2020 Seen in the Most Urban Areas
Highest death rate for males seen in most urban areas, while for females, death rate was highest in most urban and most rural areas
Cardiovascular Events Up for Individuals Hospitalized With COVID-19
Largest effect sizes seen for venous thromboembolism, heart failure, and stroke; risks highest in first 30 days